Chylomicrons Regulate Lacteal Permeability and Intestinal Lipid Absorption.
chylomicrons
endothelial cells
lipid
permeability
vascular endothelial growth factor A
Journal
Circulation research
ISSN: 1524-4571
Titre abrégé: Circ Res
Pays: United States
ID NLM: 0047103
Informations de publication
Date de publication:
04 08 2023
04 08 2023
Historique:
pmc-release:
04
08
2024
medline:
7
8
2023
pubmed:
18
7
2023
entrez:
18
7
2023
Statut:
ppublish
Résumé
Lymphatic vessels are responsible for tissue drainage, and their malfunction is associated with chronic diseases. Lymph uptake occurs via specialized open cell-cell junctions between capillary lymphatic endothelial cells (LECs), whereas closed junctions in collecting LECs prevent lymph leakage. LEC junctions are known to dynamically remodel in development and disease, but how lymphatic permeability is regulated remains poorly understood. We used various genetically engineered mouse models in combination with cellular, biochemical, and molecular biology approaches to elucidate the signaling pathways regulating junction morphology and function in lymphatic capillaries. By studying the permeability of intestinal lacteal capillaries to lipoprotein particles known as chylomicrons, we show that ROCK (Rho-associated kinase)-dependent cytoskeletal contractility is a fundamental mechanism of LEC permeability regulation. We show that chylomicron-derived lipids trigger neonatal lacteal junction opening via ROCK-dependent contraction of junction-anchored stress fibers. LEC-specific ROCK deletion abolished junction opening and plasma lipid uptake. Chylomicrons additionally inhibited VEGF (vascular endothelial growth factor)-A signaling. We show that VEGF-A antagonizes LEC junction opening via VEGFR (VEGF receptor) 2 and VEGFR3-dependent PI3K (phosphatidylinositol 3-kinase)/AKT (protein kinase B) activation of the small GTPase RAC1 (Rac family small GTPase 1), thereby restricting RhoA (Ras homolog family member A)/ROCK-mediated cytoskeleton contraction. Our results reveal that antagonistic inputs into ROCK-dependent cytoskeleton contractions regulate the interconversion of lymphatic junctions in the intestine and in other tissues, providing a tunable mechanism to control the lymphatic barrier.
Sections du résumé
BACKGROUND
Lymphatic vessels are responsible for tissue drainage, and their malfunction is associated with chronic diseases. Lymph uptake occurs via specialized open cell-cell junctions between capillary lymphatic endothelial cells (LECs), whereas closed junctions in collecting LECs prevent lymph leakage. LEC junctions are known to dynamically remodel in development and disease, but how lymphatic permeability is regulated remains poorly understood.
METHODS
We used various genetically engineered mouse models in combination with cellular, biochemical, and molecular biology approaches to elucidate the signaling pathways regulating junction morphology and function in lymphatic capillaries.
RESULTS
By studying the permeability of intestinal lacteal capillaries to lipoprotein particles known as chylomicrons, we show that ROCK (Rho-associated kinase)-dependent cytoskeletal contractility is a fundamental mechanism of LEC permeability regulation. We show that chylomicron-derived lipids trigger neonatal lacteal junction opening via ROCK-dependent contraction of junction-anchored stress fibers. LEC-specific ROCK deletion abolished junction opening and plasma lipid uptake. Chylomicrons additionally inhibited VEGF (vascular endothelial growth factor)-A signaling. We show that VEGF-A antagonizes LEC junction opening via VEGFR (VEGF receptor) 2 and VEGFR3-dependent PI3K (phosphatidylinositol 3-kinase)/AKT (protein kinase B) activation of the small GTPase RAC1 (Rac family small GTPase 1), thereby restricting RhoA (Ras homolog family member A)/ROCK-mediated cytoskeleton contraction.
CONCLUSIONS
Our results reveal that antagonistic inputs into ROCK-dependent cytoskeleton contractions regulate the interconversion of lymphatic junctions in the intestine and in other tissues, providing a tunable mechanism to control the lymphatic barrier.
Identifiants
pubmed: 37462027
doi: 10.1161/CIRCRESAHA.123.322607
pmc: PMC10530007
mid: NIHMS1915517
doi:
Substances chimiques
Vascular Endothelial Growth Factor A
0
Phosphatidylinositol 3-Kinases
EC 2.7.1.-
Chylomicrons
0
Monomeric GTP-Binding Proteins
EC 3.6.5.2
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
333-349Subventions
Organisme : NIDDK NIH HHS
ID : R01 DK120373
Pays : United States
Commentaires et corrections
Type : CommentIn
Références
Nat Commun. 2022 Jul 9;13(1):3983
pubmed: 35810168
J Cell Biol. 2012 Mar 5;196(5):641-52
pubmed: 22391038
J Cell Sci. 2015 Oct 15;128(20):3757-68
pubmed: 26359301
Invest Ophthalmol Vis Sci. 2012 Oct 11;53(11):7097-108
pubmed: 22969074
Cell. 1997 May 2;89(3):457-67
pubmed: 9150145
Circ Res. 2000 Aug 18;87(4):335-40
pubmed: 10948069
Angiogenesis. 2020 Nov;23(4):685-698
pubmed: 32783108
J Exp Med. 2012 Jul 2;209(7):1363-77
pubmed: 22689825
Science. 2018 Aug 10;361(6402):599-603
pubmed: 30093598
Nat Commun. 2016 Mar 23;7:11017
pubmed: 27005951
J Clin Invest. 2015 Nov 03;125(12):4572-86
pubmed: 26529256
Ann Nutr Metab. 2016;69 Suppl 2:28-40
pubmed: 28103608
Proc Natl Acad Sci U S A. 2015 Jan 20;112(3):761-6
pubmed: 25561555
J Exp Med. 2010 Feb 15;207(2):309-18
pubmed: 20123962
Arterioscler Thromb Vasc Biol. 2015 Feb;35(2):421-9
pubmed: 25524775
Biochim Biophys Acta. 2013 Jan;1831(1):213-22
pubmed: 22986288
Biochem J. 2011 Jul 15;437(2):169-83
pubmed: 21711246
Front Immunol. 2019 Mar 14;10:471
pubmed: 30923528
EMBO Mol Med. 2015 Oct 12;7(11):1418-25
pubmed: 26459520
Am J Physiol Renal Physiol. 2008 Jul;295(1):F153-64
pubmed: 18434385
EMBO J. 1997 Jul 1;16(13):3898-911
pubmed: 9233800
Biochemistry. 2012 Sep 25;51(38):7420-32
pubmed: 22931484
Sci Signal. 2021 Aug 03;14(694):
pubmed: 34344833
Cardiovasc Res. 2009 May 1;82(2):221-8
pubmed: 19287048
Nature. 2008 May 29;453(7195):662-6
pubmed: 18449193
Cell Mol Gastroenterol Hepatol. 2019;7(3):503-513
pubmed: 30557701
Genes Dev. 2017 Aug 15;31(16):1615-1634
pubmed: 28947496
J Cell Physiol. 2001 Sep;188(3):359-68
pubmed: 11473363
EMBO Rep. 2019 Apr;20(4):
pubmed: 30783017
JCI Insight. 2017 Mar 23;2(6):e92465
pubmed: 28352669
Elife. 2016 Jan 14;5:e12994
pubmed: 26765561
Biochem Cell Biol. 2013 Dec;91(6):404-18
pubmed: 24219282
Science. 1998 Jan 23;279(5350):558-60
pubmed: 9438848
Nat Med. 2012 Jun;18(6):967-73
pubmed: 22581286
Cell Rep. 2021 Nov 23;37(8):110030
pubmed: 34818545
Theranostics. 2021 Jan 1;11(3):1377-1395
pubmed: 33391540
Pflugers Arch. 2001 Feb;441(5):596-603
pubmed: 11294240
J Biol Chem. 2003 Oct 17;278(42):40973-9
pubmed: 12881528
J Biol Chem. 1998 Mar 20;273(12):6599-602
pubmed: 9506953
Small GTPases. 2018 Jul 4;9(4):316-321
pubmed: 27533896
J Clin Invest. 2011 Aug;121(8):2984-92
pubmed: 21765212
J Cell Biol. 2017 Dec 4;216(12):4255-4270
pubmed: 29114068
J Lipid Res. 2017 Oct;58(10):1977-1987
pubmed: 28814641
EMBO J. 2010 Apr 21;29(8):1377-88
pubmed: 20224550
Am J Pathol. 2010 Oct;177(4):2091-102
pubmed: 20802176
J Exp Med. 2018 Jan 2;215(1):35-49
pubmed: 29242199
FASEB J. 2013 Apr;27(4):1439-49
pubmed: 23271052
Am J Physiol Heart Circ Physiol. 2012 Feb 1;302(3):H724-32
pubmed: 22101521
Nat Commun. 2012;3:1208
pubmed: 23169049
Mol Cell Biol. 2008 Aug;28(15):4843-50
pubmed: 18519586
Nutrients. 2020 Feb 27;12(3):
pubmed: 32121018
J Clin Invest. 2014 Mar;124(3):929-35
pubmed: 24590278
J Exp Med. 2022 May 2;219(5):
pubmed: 35353138
J Biol Chem. 1999 Feb 5;274(6):3744-52
pubmed: 9920927
Cell Stem Cell. 2009 Mar 6;4(3):263-74
pubmed: 19265665
Oncogene. 2015 Dec 3;34(49):5971-82
pubmed: 25746002
Nat Commun. 2021 Jun 7;12(1):3350
pubmed: 34099721
J Exp Med. 2007 Oct 1;204(10):2349-62
pubmed: 17846148
J Biol Chem. 2001 Oct 19;276(42):38349-52
pubmed: 11533044
J Biol Chem. 2009 Jul 31;284(31):20936-45
pubmed: 19506078
Am J Pathol. 2012 Jun;180(6):2561-75
pubmed: 22538088
Elife. 2020 Jun 08;9:
pubmed: 32510325
Nat Commun. 2020 Aug 14;11(1):4102
pubmed: 32796823
Pharmacol Rev. 2015 Oct;67(4):1074-95
pubmed: 26419448
Trends Cell Biol. 2011 Dec;21(12):718-26
pubmed: 21924908
Cell. 2017 Aug 10;170(4):800-814.e18
pubmed: 28802047
Front Physiol. 2018 Dec 11;9:1783
pubmed: 30618798
Nat Neurosci. 2012 Oct;15(10):1391-8
pubmed: 22941110
Front Physiol. 2020 May 29;11:509
pubmed: 32547411
FEBS Lett. 2011 Feb 18;585(4):618-22
pubmed: 21281639
Pharmacol Res. 2018 Jul;133:201-212
pubmed: 29791873